Product Description:
- Bronchodilator with powerful spasmolytic effect.
- For treatment Bronchial obstruction by e.g. Chronic obstructive bronchitis and bronchial asthma.
- The bronchodilation after inhalation of ipratropium bromide is local and specific to the lungs and not of a systemic nature.
- Does not affect secretion production in the airways, mucociliary transport or gas exchange.
- Can be used in combination with adrenergic
- The result is a stronger and longer-lasting bronchodilation. The effect occurs within 15 minutes, max. effect after approx. 1-2 hours with a duration of up to 4-6 hours.
.How To Use:
- The dose is adjusted individually.
- If the dose does not produce the usual effect or the patient's symptoms worsen, a doctor must be contacted for assessment of the treatment.
Inhalation liquid:
- Daily doses >1 mg for children <12 years or >2 mg for adults and children >12 years should only be given under close medical supervision. Children: 0.25 mg ipratropium bromide 3-4 times a day.
Adults:
- 25-0.5 mg ipratropium bromide 3-4 times a day.
- Preparation/Handling
Inhalation liquid:
- Can be used undiluted.
- The 1 ml dose containers are diluted with physiological saline to a total volume of 2-4 ml or used in combination with a β 2 agonist.
Warnings And Precautions:
- Acute hypersensitivity reactions may occur in rare cases after inhalation, and may manifest as rash, urticaria , angioedema , bronchospasm, edema of the mouth and pharynx as well as anaphylaxis .
- Medicines that are inhaled can cause paradoxical bronchospasm which can be life-threatening. The treatment must then be discontinued immediately and replaced with alternative treatment. Use with caution in patients who are predisposed to narrow-angle glaucoma.
- In some cases , eye problems (e.g. Mydriasis , increased intraocular pressure, narrow-angle glaucoma and eye pain) have been reported in patients who have received ipratropium bromide alone or in combination with adrenergic β 2 agonistin the eyes.
- Pain or discomfort from the eyes, blurred vision, halo or color phenomenon, together with red eyes due to swelling of the conjunctiva or cornea, can be signs of narrow-angle glaucoma.
- In the event of such symptoms, treatment with a miotic should be initiated and an eye specialist should be contacted immediately.
- he patient is instructed in the correct use of the preparation and warned against letting the preparation get into the eyes.
- If it gets in the eyes, the eyes should be rinsed with running water.
- Use with caution in prostatic hyperplasia or bladder neck obstruction.
- Patients with cystic fibrosismay have an increased risk of gastrointestinal motility disorders when treated with ipratropium bromide.
- The patient should be encouraged to contact a doctor when the desired effect is not achieved. In case of acute deterioration of lung function, a doctor must be contacted immediately.
- Side effects such as dizziness, accommodation disturbances, mydriasis and blurred vision may occur during treatment, and caution is therefore recommended when driving or using machinery.
Ingredients:
- INHALATION LIQUID, single-dose containers 0.25 mg/ml and 0.5 mg/ml.
1 ml contents:
- Ipratropium bromide 0.25 mg.
OR:
- Ipratropium bromide 0.5 mg
